January 25, 2020
Often called "dark matter", it could alter the way cancer is detected and treated, research from The Institute of Cancer Research suggests.
April 25, 2021
A number of trials are exploring immune-oncology (IO) therapies in combination with VEGF antibodies, tyrosine kinase inhibitors (TKIs), and other IO agents as potential new strategies for patients with hepatocellular carcinoma. A presentation by Richard S. Finn, MD, during the American Association for Cancer Research Special Conference, focused on phase 3 combination studies in that setting.
April 25, 2021
University of Arizona researchers have been working for decades to develop a drug that so specifically targets a deadly kind of breast cancer that there are little to no toxic side effects.
July 14, 2018
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut volutpat rutrum eros amet sollicitudin interdum. Suspendisse pulvinar, velit nec pharetra interdum, ante tellus ornare mi, et […]
July 14, 2018
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut volutpat rutrum eros amet sollicitudin interdum. Suspendisse pulvinar, velit nec pharetra interdum, ante tellus ornare mi, et […]
July 14, 2018
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut volutpat rutrum eros amet sollicitudin interdum. Suspendisse pulvinar, velit nec pharetra interdum, ante tellus ornare mi, et […]
July 14, 2018
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut volutpat rutrum eros amet sollicitudin interdum. Suspendisse pulvinar, velit nec pharetra interdum, ante tellus ornare mi, et […]
April 25, 2021
July 12, 2018
April 25, 2021
Following last year’s accelerated approval designation, the FDA granted regular approval to sacituzumab govitecan to treat patients with triple-negative breast cancer. The FDA announced it has granted full approval to sacituzumab govitecan (Trodelvy) for the treatment of adults patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who received 2 or more prior systemic therapies, with at least 1 therapy for metastatic disease, according to an FDA press release.
April 25, 2021
The CheckMate-816 trial is the first positive phase 3 trial demonstrating a significant improvement in pathologic response with neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer. The addition of nivolumab (Opdivo) to chemotherapy improved pathological complete responses (pCR) compared with chemotherapy alone as a neoadjuvant therapy in patients with resectable non-small cell lung cancer (NSCLC)
July 12, 2018
It may be possible to vaccinate against induced NY-ESO-1 expression to produce an antigen-specific immune response in patients with high-risk myelodysplastic syndrome (MDS), according to a […]
July 12, 2018
Nivolumab immunotherapy appeared safe and feasible to administer in conjunction with radiation and chemotherapy for patients with newly diagnosed local-regionally advanced squamous cell carcinoma of the […]
July 12, 2018
A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s […]
July 12, 2018
Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. Imfinzi is a […]
July 12, 2018
New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to new data from the European Society for Medical Oncology
April 25, 2021
More metastatic breast cancer patients may be eligible to receive a treatment recently approved by the U.S. Food and Drug Administration (FDA) for a newly defined category called “HER2-low” metastatic breast cancer. October, 2022
April 25, 2021
Researchers have turned to drug delivery nanoparticles to maximize the anti-cancer STING of a molecule, pointing to a possible way to unlock the potential of a pathway that has caught the eye of the industry.
July 12, 2018
Scientists have discovered DNA-damaging molecules made by gut bacteria that may help explain why people with inflammatory bowel disease (IBD) have higher rates of colorectal cancer than those without the condition.
April 25, 2021
Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.
April 25, 2021
An estimated 2.3 million womenTrusted Source around the world received a diagnosis of breast cancer in 2020. That same year, about 685,000 women globally died from the disease.
June 15, 2018
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a way to rein in an overactive protein that drives some aggressive leukemias. The renegade molecule, MEF2C, […]
June 15, 2018
Cellular immunotherapies such as chimeric antigen receptor therapy are a promising approach for treatment of multiple myeloma. CAR T-cells have impressive activity against leukemia and lymphoma, […]
March 12, 2018
Cellular immunotherapies such as chimeric antigen receptor therapy are a promising approach for treatment of multiple myeloma. CAR T-cells have impressive activity against leukemia and lymphoma, […]
March 8, 2018
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a way to rein in an overactive protein that drives some aggressive leukemias. The renegade molecule, MEF2C, […]
March 7, 2018
While 2017 was a milestone year for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), where a combined 7 agents were approved by the FDA, […]
March 6, 2018
New compounds targeting epigenetics have shown remarkable early activity in patients with lymphoma, according to new data from the European Society for Medical Oncology
March 1, 2018
A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s […]
February 21, 2018
Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. Imfinzi is a […]
February 15, 2018
Nivolumab immunotherapy appeared safe and feasible to administer in conjunction with radiation and chemotherapy for patients with newly diagnosed local-regionally advanced squamous cell carcinoma of the […]
January 29, 2018
It may be possible to vaccinate against induced NY-ESO-1 expression to produce an antigen-specific immune response in patients with high-risk myelodysplastic syndrome (MDS), according to a […]
January 26, 2018
Venetoclax had promising clinical activity, with a high objective response rate among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with idelalisib, according […]
January 23, 2018
It may be possible to treat patients with relapsed Hodgkin lymphoma (HL) with a new engineered T-cell approach that is less toxic and does not require […]
January 23, 2018
The combination of nivolumab and ipilimumab yielded high response rates and encouraging survival outcomes in a cohort of previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite […]
January 18, 2018
This award signifies MHOA’S laboratory’s commitment to performing quality patient testing and overall laboratory practices. The Laboratory Excellence Award is achieved by those laboratories that are […]
January 1, 2018
Phase 3 results from the ECHELON-1 study, presented at the 59th Annual Meeting & Exposition of the American Society of Hematology, showed superior modified progression-free survival […]
December 19, 2017
Updated analyses are validating the efficacy of copanlisib in the treatment of relapsed or refractory indolent B-cell lymphoma. Investigators reported at the 2017 annual meeting of […]
December 15, 2017
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast […]
December 12, 2017
Clinicians may soon have a valuable new therapeutic option for treating patients with cutaneous T-cell lymphoma (CTCL). Results of a randomized phase III study presented at […]